Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
about
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.Serological detection of cutaneous T-cell lymphoma-associated antigensDetection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemiaSerological identification and expression analysis of gastric cancer-associated genesSurvey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responsesCancer/testis antigens: an expanding family of targets for cancer immunotherapymRNA expression of tumor-associated antigens in melanoma tissues and cell linesHuman Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune responseAn unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactionsPre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapyCancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myelomaCML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemiaSeroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients.CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.Immunological and pathobiological roles of fibulin-1 in breast cancer.Molecular characterization of virus-induced autoantibody responses.Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.Identification of Metastasis Associated Antigen 1 (MTA1) by Serological Screening of Prostate Cancer cDNA Libraries.Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma.Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.Melanoma: tumor microenvironment and new treatments.Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomasMultiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.Oral vaccination with attenuated Salmonella enterica strains encoding T-cell epitopes from tumor antigen NY-ESO-1 induces specific cytotoxic T-lymphocyte responses.HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancerRegulation of cancer germline antigen gene expression: implications for cancer immunotherapy.Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma.Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.New methods for assessing T-cell responses.Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaCD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients.
P2860
Q24531314-69FC07A6-EF91-4FAE-87AD-DC141DF7C972Q24533572-9859D761-0672-436E-8D7C-01DE63569DDDQ24544114-D1564B33-D6FF-4E1C-98A1-0EC26BEF53B1Q24604091-C82592FA-5DB8-4C1B-8637-BBA6B47C0297Q24642763-69D48D22-8114-468F-90A1-4CFCD1FF22B0Q24678759-7D086C1F-A231-45AD-A488-35F2D3EB2233Q28215652-42B319EC-4D94-4018-8F07-913983D99FFDQ28218733-C81EF57C-9479-4328-80FA-6D4606378492Q28251022-BB59A738-5391-49C8-927D-731719300735Q28264336-3371B051-5C36-4DC1-8D52-9F9FB8CF6167Q28344557-8581C671-B9BE-4897-863F-09643F5FED79Q28648164-57D1C211-8DC5-4C2C-B531-8AF57D8F819AQ30679410-DA7C917D-46D9-4C29-9030-6ABF009CB6CAQ30785776-668D322F-AAA3-485A-8164-46252B79611BQ30859024-6EE46338-BCB2-4A02-BF97-5D82ED009487Q31033973-DFDB677D-58C3-41D0-92BE-553A0BE9D63EQ31110185-8E5B6626-2E9A-4086-9C38-51B8C0C4E13AQ33195347-39A7BADF-A125-4335-810C-9DE0DF9959B2Q33379115-D7DC9E06-226D-4C37-B427-48A82A6C32C3Q33494714-9B69AEB1-8D48-4651-AAFC-7B78E82F115CQ33551458-997DF8FA-135E-422B-A223-0F878F110EB4Q33675676-85C6AB6D-A3EA-4393-92DF-265B5D2A4B8DQ33734053-6F4D831E-2E3A-4F77-A71C-ADFD3B64BFF8Q33855568-AAA87148-F735-45A4-8126-4DF1CB8BF838Q33909195-E0A2D529-7A9D-413F-BC2B-FB28B49677C6Q33909892-B8C896B1-97CF-48E1-989A-ADEF4831F06FQ33957165-6C206457-FE89-4E47-8051-36A7EF1B1B24Q33967422-A98F4550-76BF-4C6A-A276-E2DEDB00D0C8Q33999909-9EA6D870-3C1F-4AC1-B060-74938D2A773EQ34076691-A5F7F709-0A1D-45A5-B3C0-BCA6854EAD9DQ34080118-F9CA66CA-DAB4-4678-90F2-713C226F3A63Q34111719-D0CB7F8F-D36A-485B-A18F-C0EE7C362A9CQ34111757-CD28597B-5D6D-431E-9ECC-00CEA3F00590Q34111789-567AA4DC-BC0B-4EB7-A339-3644386F608FQ34154427-D956CA40-F481-4E84-AE36-8FFFC78A0EB6Q34161579-60FF0979-8F31-46E2-9462-D834A2681E0AQ34221846-B29B0C70-1052-449B-9797-F4646A22AD3BQ34325790-D3E57E53-BDC4-472C-9C7C-AD39CF74F850Q34388367-6028179D-6D82-43E8-9374-B8DE50F75A92Q34465380-705DD90A-2029-4BB2-B7FD-735B91DC21C3
P2860
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Monitoring CD8 T cell response ...... and cellular immune responses.
@ast
Monitoring CD8 T cell response ...... and cellular immune responses.
@en
type
label
Monitoring CD8 T cell response ...... and cellular immune responses.
@ast
Monitoring CD8 T cell response ...... and cellular immune responses.
@en
prefLabel
Monitoring CD8 T cell response ...... and cellular immune responses.
@ast
Monitoring CD8 T cell response ...... and cellular immune responses.
@en
P2093
P2860
P50
P356
P1476
Monitoring CD8 T cell response ...... and cellular immune responses
@en
P2093
A Jungbluth
E Stockert
P2860
P304
P356
10.1073/PNAS.97.9.4760
P407
P577
2000-04-01T00:00:00Z